Edesa Biotech Inc expected to post a loss of 58 cents a share - Earnings Preview
Edesa Biotech Inc <EDSA.OQ> expected to post a loss of 58 cents a share - Earnings Preview
Edesa Biotech Inc EDSA.OQ EDSA.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Edesa Biotech Inc is for a loss of 58 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Edesa Biotech Inc is $19.00, about 263.3% above its last closing price of $5.23
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.28 | -0.26 | -0.49 | Missed | -88.5 |
Dec. 31 2026 | -0.50 | -0.45 | -0.28 | Beat | 37.8 |
Sep. 30 2025 | -0.28 | -0.27 | -0.32 | Missed | -20 |
Jun. 30 2025 | -0.28 | -0.26 | -0.25 | Beat | 5.1 |
Mar. 31 2025 | -0.36 | -0.29 | -0.30 | Missed | -1.7 |
Dec. 31 2024 | -0.31 | -0.31 | -0.48 | Missed | -54.8 |
Sep. 30 2024 | -0.63 | -0.54 | -0.29 | Beat | 46.3 |
Jun. 30 2024 | -0.71 | -0.58 | -0.52 | Beat | 10.3 |
This summary was machine generated August 4 at 11:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)